Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
CLINT1 antibody was raised against synthetic peptide located between aa229-278 of human CLINT1 (Q9BZQ6, NP_079467). Percent identity by BLAST analysis: Human, Chimpanzee, Gorilla, Orangutan, Gibbon, Monkey, Galago, Marmoset, Mouse, Rat, Elephant, Dog, Bovine, Bat, Rabbit, Horse, Pig, Guinea pig (100%); Opossum, Platypus (92%).
LS-E22826 - Lyophilized - 100 µg - $145.00
Immunizing peptide used to generate LS-C145831. Useful for pre-absorption and neutralization of the antibody's antigen binding site.
Lyophilized from PBS, 0.09% sodium azide, 2% sucrose
Centrifuge the vial prior to opening. Reconstitute with sterile distilled water to a concentration of 1 mg/ml. Vortex and centrifuge again.
Long term: -20°C, the use of 50% glycerol is recommended if storing aliquots in -20°C for long term use (up to 1 year); Short term (less than 1 week): 4°C. Avoid freeze-thaw cycles.
CLINT1 is a protein with similarity to the epsin family of endocytic adapter proteins. The encoded protein interacts with clathrin, the adapter protein AP-1 and phosphoinositides. This protein may be involved in the formation of clathrin coated vesicles and trafficking between the trans-Golgi network and endosomes. Mutations in this gene are associated with a susceptibility to schizophrenia and psychotic disorders. Alternate splicing results in multiple transcript variants.